Free tool
Rare disease stocks
We cover 79 companies grouped under the Rare disease theme. The median market value in the group is $81.15M. Across the group, the median move over the past trading day is +1.41%. 50% of the 76 with a 200-day average trade above it. Price change over the past year runs from −87.9% to +206.1% across the middle 80 percent of the group, with a median of +5.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
79 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +182.02% |
| IMVT | Immunovant, Inc. | $8.95B | Mid cap | +192.14% |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.78B | Mid cap | +14.26% |
| SRRK | Scholar Rock Holding Corporation | $7.09B | Mid cap | +74.77% |
| ORKA | Oruka Therapeutics, Inc. | $6.74B | Mid cap | +601.72% |
| LQDA | Liquidia Corporation | $6.31B | Mid cap | +168.53% |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.17B | Mid cap | +142.74% |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.13B | Mid cap | +49.03% |
| DNTH | Dianthus Therapeutics, Inc. | $6.13B | Mid cap | +378.90% |
| TVTX | Travere Therapeutics, Inc. | $6.06B | Mid cap | +288.91% |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.98B | Mid cap | +36.58% |
| GRFS | Grifols, S.A. | $5.44B | Mid cap | −17.62% |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +102.62% |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +209.16% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.17B | Mid cap | +340.71% |
| MANE | Veradermics, Incorporated | $4.11B | Mid cap | +171.13% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +52.72% |
| CLDX | Celldex Therapeutics, Inc. | $3.24B | Mid cap | +87.96% |
| IRON | Disc Medicine, Inc. | $3.16B | Mid cap | +38.71% |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +58.44% |
| VRDN | Viridian Therapeutics, Inc. | $2.74B | Mid cap | +30.21% |
| PHVS | Pharvaris N.V. | $2.62B | Mid cap | +57.76% |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −9.60% |
| TRVI | Trevi Therapeutics, Inc. | $2.56B | Mid cap | +146.57% |
| VERA | Vera Therapeutics, Inc. | $2.54B | Mid cap | +65.32% |
| NKTR | Nektar Therapeutics | $2.52B | Mid cap | +176.20% |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +17.16% |
| MLYS | Mineralys Therapeutics, Inc. | $2.32B | Mid cap | +78.70% |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.32B | Mid cap | +46.03% |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.23B | Mid cap | +38.03% |
| ZBIO | Zenas BioPharma, Inc. | $2.20B | Mid cap | +103.93% |
| STOK | Stoke Therapeutics, Inc. | $2.16B | Mid cap | +77.32% |
| ADMA | ADMA Biologics, Inc. | $2.14B | Mid cap | −42.86% |
| PVLA | Palvella Therapeutics, Inc. | $2.14B | Mid cap | +195.71% |
| GOSS | Gossamer Bio, Inc. | $99.97M | Micro cap | −91.33% |
| FBIO | Fortress Biotech, Inc. | $94.38M | Micro cap | +23.58% |
| PLYX | Polaryx Therapeutics, Inc. | $94.21M | Micro cap | −94.66% |
| RLYB | Rallybio Corporation | $89.67M | Micro cap | +262.65% |
| TENX | Tenax Therapeutics, Inc. | $86.82M | Micro cap | −60.81% |
| TELO | Telomir Pharmaceuticals, Inc. | $81.15M | Micro cap | −19.18% |
| FBIOP | Fortress Biotech, Inc. | $71.45M | Micro cap | +141.55% |
| SPRO | Spero Therapeutics, Inc. | $70.76M | Micro cap | −33.51% |
| RNTX | Rein Therapeutics Inc. | $69.01M | Micro cap | −32.20% |
| IMA | ImageneBio, Inc. | $63.80M | Micro cap | −60.78% |
| ATYR | aTyr Pharma, Inc. | $55.91M | Micro cap | −88.95% |
| SCYX | SCYNEXIS, Inc. | $51.64M | Micro cap | +514.20% |
| NSRX | Nasus Pharma Ltd. | $48.01M | Micro cap | −48.69% |
| MCRB | Seres Therapeutics, Inc. | $46.81M | Micro cap | −74.00% |
| GRCE | Grace Therapeutics, Inc. | $46.28M | Micro cap | −32.31% |
| MREO | Mereo BioPharma Group plc | $44.97M | Micro cap | −83.82% |
| EDSA | Edesa Biotech, Inc. | $42.90M | Micro cap | +83.88% |
| QNCX | Quince Therapeutics, Inc. | $34.05M | Micro cap | +95.76% |
| NNVC | NanoViricides, Inc. | $32.93M | Micro cap | −12.84% |
| BRNS | Barinthus Biotherapeutics plc | $26.96M | Micro cap | −44.77% |
| JSPR | Jasper Therapeutics, Inc. | $23.96M | Micro cap | −75.67% |
| TVRD | Tvardi Therapeutics, Inc. | $23.74M | Micro cap | −93.77% |
| RVX.TO | Resverlogix Corp. | $23.62M | Micro cap | +5.00% |
| COCP | Cocrystal Pharma, Inc. | $21.77M | Micro cap | −26.62% |
| VYNE | VYNE Therapeutics Inc | $19.07M | Micro cap | +8687.69% |
| KTTA | Pasithea Therapeutics Corp. | $18.71M | Micro cap | −21.90% |
| CALC | CalciMedica, Inc. | $17.10M | Micro cap | −78.92% |
| CMMB | Chemomab Therapeutics Ltd. | $16.85M | Micro cap | −33.91% |
| HIND | Vyome Holdings, Inc. | $15.65M | Micro cap | −80.23% |
| QNRX | Quoin Pharmaceuticals, Ltd. | $10.18M | Micro cap | −31.02% |
| AZTR | Azitra, Inc. | $9.55M | Micro cap | −78.97% |
| IMRN | Immuron Limited | $9.20M | Micro cap | −36.84% |
| SNGX | Soligenix, Inc. | $8.81M | Micro cap | −87.06% |
| XCUR | Exicure, Inc. | $7.79M | Micro cap | −79.90% |
| INM | InMed Pharmaceuticals Inc. | $7.69M | Micro cap | −35.43% |
| PULM | Pulmatrix, Inc. | $5.84M | Micro cap | −67.81% |
| JAGX | Jaguar Health, Inc. | $4.78M | Micro cap | −98.52% |
| CVKD | Cadrenal Therapeutics, Inc. | $4.74M | Micro cap | −87.58% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.48M | Micro cap | +205.34% |
| GRI | GRI Bio, Inc. | $4.28M | Micro cap | −95.14% |
| XRTX | XORTX Therapeutics Inc. | $4.11M | Micro cap | −44.74% |
| SXTP | 60 Degrees Pharmaceuticals, Inc. | $3.97M | Micro cap | −78.10% |
| MTNB | Matinas BioPharma Holdings, Inc. | $2.90M | Micro cap | −90.82% |
| APLI.TO | Appili Therapeutics Inc. | $1.44M | Micro cap | −25.00% |
| VBIO | Valion Bio, Inc. | $660.05K | Micro cap | −95.00% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.